




Peptide solutions to infection and inflammation problems

Precision control of immunity
Using new small ezrin-derived peptides.

Amplification of T Cell and B Cell responses.

Regulation of inflammation by inhibition of
pro-inflammatory cytokine expression.

Safety & Efficacy of ezrin-derived peptides
already established in humans



Immunity is a metastable signalling matrix, not a binary switch


Disease emerges at both ends of the immune response spectrum. The opportunity is to restore healthy balance — not simply to turn different pathways of immunity off or on by continuous exposure to small molecule or monoclonal antibody antagonists or agonists.



Newal's thesis

Ezrin peptide intervention can shift signalling back toward the health zone. Clinical success in treatment of respiratory infections and sex infections of viral, bacterial and fungal origin, as well as control of inflammatory disease such as ulcerative colitis, ankylosing spondylitis and Long COVID. No safety issues detected with the ezrin peptide platform

The ezrin peptide platform influences protein-protein interactions



1

SITE OF ACTION & DELIVERY

Ezrin peptide solutions act on mucous membranes. Active in oral solution delivery, sugar-peptide pills, as topical emulsions and by peptide solution injection.

2

ALLOSTERIC CONFORMATION CHANGE

Ezrin peptides modulate ezrin-receptor-kinase multi-protein signalling complexes.

3

SECONDARY SIGNALLING

Ezrin peptides down-regulate pro inflammatory cytokines : IL-1b, IL-6, IL-8, TNFa. But upregulate RANTES-CCL5, a T & B cells immune amplifier

4

SELECT REQUIRED EFFECT

The specific biological activity of ezrin peptides sequence-dependant. Screen designed candidates through relevant in vitro assays.

The asset is the learning system — each cycle sharpens the next design decision.

Small ezrin-derived peptides are designed to reset the immune system into its health zone

Ezrin peptides act on complex systems not single targets

01 Origin


Reverse engineering from HIV in London: viral gp120 mimics human ezrin. Ezrin is a core protein of the multi-protein immunological synapse. The first ezrin peptide cured a terminal AIDS patient, unlocking development funding in 1990s. The first ezrin peptide product was launched in 2001 in Russia where broad-spectrum efficacy and safety was first established.

02 Clinical Applications

Although first developed as an oral HIV and AIDS therapeutic, we discovered that ezrin peptides can effectively treat any drug-resistant infection of any viral, bacterial, fungal and even protozoan origin. It was later discovered that ezrin peptides are effective therapy for inflammatory diseases such as Ulcers, IBD and AS. Further tissue regeneration and anti cancer immunity applications were revealed.

03 New Products

New ezrin peptide sequences tailored for novel biological activities leading to patented composition of matter




CONCEPTUAL VISUAL — NOT AN EXPERIMENTAL STRUCTURE

Product Development Plan for ezrin-derived peptide products

Efficient collaboration partnerships with Service Providers.



01 Peptide Synthesis

Ezrin peptides are currently produced in an FDA approved facility of Chinese Peptide Company, Hangzhou, Zhejiang, China which manufactures high-quality peptides at low-prices and is an integrated CRO & CDMO. Newal Peptides may be produced by other companies



02 In Vitro Immunology

Immuone in Stevenage UK has already expressed interest in collaborating on in vitro immunology of ezrin peptides. Newal Peptides may be tested by other companies



03 In Vivo animal/clinical development

Dr Holms is the original founder of hVIVO PLC a company that specialises in drug development to human clinical trials. Newal Peptides may be trialled by other companies



The management team has significant experience building biotech companies and solving medical problems for patients

FOUNDER AND CEO

**Dr Rupert
Holms**
London



**Former Life Sciences Investment Manager at Lombard Odier
Inventor of the ezrin peptide platform. Founded two successful biomedical businesses:
Nearmedic in Moscow, ~ £120m immune-pharmaceutical business & hVIVO PLC in London, LSE listed ~£50 million drug screening and clinical trial business**

CHAIRMAN

**Dr John
Abeles**
New York



Biotech founder and financier based in New York, responsible for multiple start-ups and successful exits via IPOs or corporate acquisitions

CHIEF MEDICAL OFFICER

**Dr Phillip
Hay**
London



Consultant at Guy's and St Thomas' NHS Foundation Trust, London. Specialist in sexual health

Other specialists shall join the team after the completion of the funding round

New Capital shall fund new composition of matter intellectual property based on Generation-4 ezrin peptide secret-know-how

De-risked Program: decades of clinical use of ezrin peptides

Ezrin peptides were reverse-engineered from HIV & AIDS in London in 1994. The first ezrin peptide product HEP-1 Gepon, developed in Moscow for drug resistant sex-infection, has been on the Russian market since 2001 where new clinical applications were discovered. Ezrin peptide RepG3 has been used in volunteers to treat Long COVID and resulted in new discoveries in the treatment of inflammatory co-morbidities. New peptides designed but new funds required for testing.



NEXT VALUE INFLECTION

New patent protected peptides with pre-clinical evidence to support a clinical program in Anti-Microbial-Resistance or Chronic Inflammation

The ezrin peptide approach creates safe & effective medicine

Affordable successful treatment of unmet medical needs

MODALITY	DELIVERY	PATIENT COST	MANUFACTURE	UTILITY
Cell therapies	Catheter/injection	Very High	Complex Biologics	Individual Patient Specific
Antibodies	Injection	High	Biologic	Target-dependent Small numbers of patients
Small molecules	Injection/oral	modest	Specialised chemistry	Large numbers of patients Lower specificity
NEWAL PEPTIDES	Oral spray inhalation, Topical & sugar-peptide pills	modest	Peptide automated synthesis	Large Population Utility High Specificity
PATENTS				
Generation-4 Ezrin Peptide Secret-Know-How			Patent applications	To be Filed 2028 (expire 2048)
Generation-3 Ezrin-Derived Peptides and Pharmaceutical Compositions Thereof			Granted Patents	Expire 2036
Generation-2 Regulatory/unfolding peptides of ezrin			Granted Patents	Expired 2020
Generation-1 AIDS Prophylactics			Granted Patents	Expired 2015

Capital Plan, Business Evolution and Profitable Growth

Vision to be a supplier of affordable safe and effective peptide medicines to millions of customers

Efficacy dose 2mg per patient per day, Cost of Peptide £1 per day, Cost of treatment £10 per day

01

£ 2 million new capital for lead peptide selections, peptide synthesis, pre-clinical mechanism of action, kinetics and safety, Generation-4 ezrin peptide knowhow development, new patent protection

Runway: 2 years

02

£ 3 million new capital for IND, clinical phase 1 and clinical phase 2 of candidate peptides. Safety and efficacy of respiratory infections with an inflammatory component.

Runway: 2 years

03

£ 7 million new capital for clinical phase 3. Multi centre clinical trials for respiratory infections with an inflammatory component, targeting product approvals in at least one territory. UK / USA / EU

Runway: 2 years

04

£20 million to build peptide manufacturing plus product packaging. Pharmaceutical business development.

Runway: 4 years to positive cash flow and profits

RAISE

£2,000,000

RUNWAY

30 months

END MILESTONE

Peptide Candidate
For Clinical Trials



Peptide solutions to infection and inflammation problems

A total investment of £2,000,000 in New Ordinary Shares.

THE ASK

01

Raising up to £2,000,000 by the Private Placing of a New Issue of Ordinary Shares of NewalR&D Ltd: Registered Office Address: 71-75 Shelton Street, Covent Garden, London WC2H 9JQ, Registered In England and Wales, Company Number: 09243410 (The Company)

02

On receipt of a total investment of £2,000,000 in new equity capital, in the Company bank account, peptide designs may be tested in vitro, new patent applications may be filed, and least one new peptide may be selected to commence clinical evaluation by the Company, in about 24 months of receipt of the total £2,000,000 in new equity capital

03

The Company plans to issue additional shares to finance its development program.

04

The targeted IPO Exit Value is £100+ million, and the targeted Acquisition Exit Value is £1 Billion+

05

THANK YOU FOR YOUR ATTENTION: CONTACT

drupertholms@googlemail.com rupeholms@newalrnd.com www.newalrnd.com

M +44 780 3042576

